Testing dapagliflozin and bosentan for large vessel vasculitis
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests two drugs, dapagliflozin and bosentan, to see if they help people with large vessel vasculitis who have been in remission for at least 6 months. The goal is to prevent flares and improve blood vessel health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with large vessel vasculitis and it has been stable (in remission) for 6 months or longer.
- You are 18 years or older.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You do not have congestive heart failure or a history of severe allergic reactions to similar drugs or foods.
- You are able and willing to attend study visits and give informed consent.
- You are not currently taking any medications that should not be taken with bosentan or dapagliflozin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called bosentan, which is usually used for other conditions, can help calm the inflammation in giant cell arteritis and reduce symptoms. You would take it in addition to your usual treatment, and it might help lower the dose of steroids you need.
This trial tests a medicine called upadacitinib (an anti-JAK pill) for people with giant cell arteritis that affects the large arteries, especially the aorta. It is for those whose disease is active despite trying another treatment called tocilizumab, and aims to reduce inflammation and prevent damage.
This study tests a new type of PET/CT scanner that takes images of a larger area of the body to better see inflammation in the blood vessels in people with large vessel vasculitis (LVV). It aims to improve how doctors detect and monitor this condition.
This study uses PET and MRA scans to predict damage to large blood vessels in people who have or may have large vessel vasculitis (LVV). It aims to find at-risk patients early so they can get better care. You'll need to be willing to have both scans and come back for long-term check-ups.
This trial tests whether adding pirfenidone (a drug that reduces scarring) to your usual treatment helps limit blood vessel thickening and scarring in Takayasu arteritis. You must still have some signs of active disease despite being on standard therapy.
This trial tests the drug tocilizumab (Actemra) to see if it helps reduce swelling in the aorta in people with giant cell arteritis (GCA) who are newly diagnosed or have had a flare. It may offer a targeted treatment for aortitis without using high-dose steroids.
Hear when a new Large Vessel Vasculitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.